SQRAY, the industry leader in integrated digital intelligence pathology solutions, has completed over 100 million RMB in Series B financing, which was exclusively invested by SDIC. The funding will be used for team expansion, accelerated clinical validation and commercialization.
Founded in 2013, SQRAY, with its main creative team all from Tsinghua University, is a high-tech enterprise integrating R&D, production and commercialization. Since its establishment, SQRAY has always insisted on becoming “the leader of pathology digitalization, the creator of pathology informatization, the integrator of pathology intelligence, and the advocate of functional pathology”. SQRAY has successfully researched and developed digital and informatized solutions for pathology, such as whole slide scanning image system, fluorescence scanning image system, and microscopic image information system (MIIS).
The development of digital pathology industry will change the traditional pathology workflow mode, which can greatly improve the accuracy and efficiency of pathology diagnosis, and promote the sharing and collaboration of medical resources.SQRAY is committed to building an ecological network of integrated solutions for digitalization, informatization, and intellectualization of pathology, and is striving to promote the standardization of the pathology industry. SQRAY has reached cooperation with more than 100 hospitals, head third-party diagnostic companies, and AI companies, and has helped the pathology departments of many top tertiary hospitals in China to build a holistic solution for general digital intelligence, while helping the construction of the national pathology standard database, and has built a provincial pathology consultation platform centered on the Anhui Provincial Hospital to promote the development of China’s digital intelligence pathology level.
Mr. Huang Qiang, General Manager of SQRAY, said that the market of clinical pathology segment is huge and there are many opportunities, and SQRAY can now provide customers with personalized intelligent pathology full set of overall solutions after 10 years of development, and the company has been committed to becoming an innovative leader in the digital pathology industry. The financing is very grateful for the recognition of SQRAY by the investment team of China Investment Corporation, and also marks that SQRAY has entered a new stage of development. In the future, the company will continue to increase the investment in innovation and R&D, in order to promote the development of new products and solutions, and constantly improve the quality and competitiveness of its products, and to promote the standardization of pathological diagnosis with digitization, informatization, and intelligence to enhance the level of digital intelligence in Chinese general pathology in an all-round way.
Meanwhile, Mr. Zhang Hongling, Sales Director of SQRAY, said that the company will also intensify its efforts to expand the pathology market, actively seek various channels and opportunities to expand the company’s market share, and will further expand the international market, explore new business opportunities, and establish close cooperation with internationally renowned partners, including Olympus.
SDIC said that pathology examination, as a “doctor’s doctor”, is the “gold standard” for the diagnosis of most of the diseases, especially cancer, but at present, the pathology department is still in a very backward stage compared with the other two major diagnostic departments, the laboratory and imaging department. Pathology is the only department in the hospital that has not been penetrated by digital intelligence technology. SQRAY’s pathology slide scanning and imaging system and the corresponding informatization and intelligent technology can help the hospital pathology department to improve diagnostic accuracy and work efficiency in the future. At present, the main performance parameters of SQRAY’s products have been better than the same type of products of large foreign life science instrument companies, and the products have covered hundreds of domestic tertiary hospitals, head of third-party diagnostic companies and AI companies, which is a very excellent performance in the domestic life science instrument industry, and in the future, CIC will continue to help the company to improve the upstream supply chain construction and overseas market expansion to help the company to become a domestic pathology department. In the future, CIC Merchants will continue to help the company to improve the upstream supply chain construction and overseas market expansion, and help the company to become a leading enterprise of one-stop solution for pathology.